Treatment with immunoglobulin replacement therapy is often used to boost antibody levels in an effort to reduce infection risk. "Many of the studies supporting the use of immunoglobulins to reduce ...

Immunoglobulin replacement therapy in CLL patients does not reduce serious infection risk, despite increased usage over 14 years. The study found higher infection rates during immunoglobulin therapy ...

Treatment with immunoglobulin replacement therapy is often used to boost antibody levels in an effort to reduce infection risk. "Many of the studies supporting the use of immunoglobulins to reduce ...

(WASHINGTON, July 31, 2025) — In patients with chronic lymphocytic leukemia (CLL), regular treatment with immunoglobulin replacement therapy was not associated with a reduced risk of serious ...

Please provide your email address to receive an email when new articles are posted on . Serious infections in patients with chronic lymphocytic leukemia have doubled despite increased use of ...

Findings showed after 52 weeks, significant improvements in 2MWD and 6MWD were seen with Flebogamma 5% DIF 1mg/kg compared with placebo. Topline data were announced from a phase 2/3 trial evaluating ...

A recent paper in Nature Biotechnology examines problems and solutions for antibody-based therapies for solid pancreatic ...

Oct 17 (Reuters) - (This Oct. 17 story has been corrected to say that the drug reduced some types of respiratory infection, not all, in the headline and paragraphs 1 and 2) Merck (MRK.N), opens new ...

Early results reveal how a single‑cell spatial platform maps stromal barriers that limit antibody delivery and target ...